Patents Examined by Sergio Coffa
  • Patent number: 11999804
    Abstract: An object of the present invention is to provide an excellent treatment agent for a lysosomal storage disease. According to the present invention, there is provided a treatment agent for a lysosomal storage disease including a cell structure which includes a plurality of biocompatible polymer blocks and a plurality of cells of at least one type and in which at least one of the polymer blocks is disposed in gaps between the plurality of cells.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: June 4, 2024
    Assignees: FUJIFILM Corporation, KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
    Inventors: Kentaro Nakamura, Tsukasa Kitahashi, Rie Hando, Satoshi Gojo, Daisuke Kami
  • Patent number: 11992036
    Abstract: A method of alleviating symptoms of, or treating, pancreatic beta-cell damage in a subject includes a step of identifying a subject having pancreatic beta-cell damage. Multiple cycles of a diet protocol are administered to the subject. The diet protocol includes administering of a fasting mimicking diet and a re-feeding diet where the fasting mimicking diet is provided for a first time period and the re-feeding diet is provided for a second time period.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: May 28, 2024
    Assignee: University of Southern California
    Inventors: Valter D. Longo, Chia-Wei Cheng
  • Patent number: 11987647
    Abstract: Disclosed are cell penetrating peptides and compositions comprising such peptides that can be used to deliver agents to various cell types.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: May 21, 2024
    Assignee: Ohio State Innovation Foundation
    Inventor: Dehua Pei
  • Patent number: 11981710
    Abstract: Described herein are proteins comprising an ankyrin repeat domain having an N-terminal capping module with improved properties, as well as corresponding protein libraries, pharmaceutical compositions and nucleic acids encoding such proteins. In other aspects, the disclosure relates to methods using such proteins, corresponding protein libraries or pharmaceutical compositions.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: May 14, 2024
    Assignee: Athebio AG
    Inventors: Johannes Schilling, Patrik Forrer
  • Patent number: 11976137
    Abstract: The present invention relates to synthetic polypeptide compounds which bind to a class A G-protein-coupled receptor, the Apelin receptor. These compounds may act as apelin receptor antagonists. These compounds and compositions comprising them may be useful in the treatment of diseases, such as cancer.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: May 7, 2024
    Assignee: Cambridge Enterprise Limited
    Inventors: Anthony Peter Davenport, Robert Charles Glen, Janet Julie Maguire
  • Patent number: 11976100
    Abstract: The present disclosure provides methods for treating or ameliorating a myelin associated disease or a mitochondria associated disease that comprising administering to a subject in need thereof a frataxin replacement therapeutic compound, e.g., a fusion protein comprising frataxin.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: May 7, 2024
    Assignee: Larimar Therapeutics, Inc.
    Inventor: Joan David Bettoun
  • Patent number: 11965006
    Abstract: This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWW????GLLG?LLG?V??VIK?L??I (SEQ ID No. 2), LKKWWK??KGLLGGLLGKV??VIK (SEQ ID No. 12), and ?KK??KK?KG?LGGL?GK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: April 23, 2024
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Berthony Deslouches, Yuanpu Di
  • Patent number: 11957762
    Abstract: Disclosed herein, are recombinant polypeptides comprising one or more homologous amino acid repeats; and, non-immunogenic bioconjugates comprising recombinant polypeptides comprising one or more homologous amino acid repeats and one or more therapeutic agents. Also, disclosed herein are pharmaceutical compositions including the recombinant polypeptides; and methods of administering the recombinant polypeptides to patients for the treatment of cancer or infections.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: April 16, 2024
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Mingnan Chen, Hyung Jin Cho, Peng Wang, Shuyun Dong, Peng Zhao
  • Patent number: 11938166
    Abstract: The present invention provides compositions and formulations comprising glutathione with or without thiocyanate and methods of use thereof to treat diseases and disorders in mucosal/epithelial tissue.
    Type: Grant
    Filed: June 15, 2021
    Date of Patent: March 26, 2024
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Roland R. Arnold, David C. Henke
  • Patent number: 11932705
    Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: March 19, 2024
    Assignees: MERCK SHARP & DOHME LLC, RA PHARMACEUTICALS, INC.
    Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Ketki Ashok Dhamnaskar, Zhong Ma, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Aurash Shahripour, Yusheng Xiong
  • Patent number: 11911436
    Abstract: The present disclosure provides amphiphilic peptide chaperones. Also provided are their incorporation into pharmaceutical compositions and methods of use for preventing or reducing a source of stress in cells and for the treatment of disorders including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), cataract, age-related macular degeneration (AMD), glaucoma, and retinitis pigmentosa.
    Type: Grant
    Filed: June 2, 2022
    Date of Patent: February 27, 2024
    Assignee: The Curators of the University of Missouri
    Inventors: Santhoshkumar Puttur, Krishna Sharma, Sundararajan Mahalingam
  • Patent number: 11905337
    Abstract: Provided are a novel peptide, a polynucleotide encoding the peptide, an expression vector including the polynucleotide, and a pharmaceutical composition including the peptide, a quasi-drug composition including the peptide, and a health functional food composition including the peptide.
    Type: Grant
    Filed: May 5, 2022
    Date of Patent: February 20, 2024
    Assignee: HYSENSBIO
    Inventors: Joo Hwang Park, Ji Hyun Lee
  • Patent number: 11897933
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: February 13, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
  • Patent number: 11884745
    Abstract: The present invention is a method for removing lipopeptides from solutions and changing their structure from cyclic to linear. The lipopeptide capture and sequestration takes place from solutions containing water through sorption. In the case of cyclic lipopeptides, in which the peptide ring is closed by a lactone bond, sorption is additionally associated with hydrolysis reactions occurring on the surface of active carbon, leading to linearization as a result of breaking the lactone bond.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: January 30, 2024
    Assignee: INVENTIONBIO SP. Z O. O.
    Inventors: Hanna Faltynowicz, Marek Kulazynski, Marcin Lukaszewicz
  • Patent number: 11872266
    Abstract: The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: January 16, 2024
    Assignee: Eli Lilly and Company
    Inventors: Michael Patrick Akers, Chi A. Nguyen, Chad D. Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte, Ranajoy Majumdar
  • Patent number: 11872264
    Abstract: The present invention is in the field of medicine and provides means and methods for the treatment, prevention or amelioration of osteoarthritis. More in particular, it provides a peptide for use in the treatment, amelioration or prevention of osteoarthritis, wherein the peptide is between 12 and 28 amino acids in length and comprises an amino acid sequence according to SEQ ID NO: 16 or a variant thereof according to formula 2, wherein the amino acid sequence of said peptide is comprised in SEQ ID NO: 34 or a variant thereof according to formula 1.
    Type: Grant
    Filed: October 11, 2021
    Date of Patent: January 16, 2024
    Assignee: Chondropeptix BV
    Inventors: Tim Johannes Maria Welting, Marjolein Maria Johanna Caron
  • Patent number: 11866518
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of thymic stromal lymphopoietin (TSLP). The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in preventing, suppressing or treating a disease or disorder mediated by TSLP.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: January 9, 2024
    Assignee: BicycleTx Limited
    Inventors: Frank Narjes, Tor Svensson, Pavol Zlatoidsky, Lotta Hidestal, Liuhong Chen, Michael Skynner, Sophie Watcham
  • Patent number: 11866469
    Abstract: The present disclosure relates to compositions and methods for modulating gene expression and in particular to DNA binding proteins and their use for increasing expression of Klotho. In some examples, the present disclosure provides an isolated or recombinant DNA binding protein comprising or attached to a transcriptional activation domain wherein the DNA binding protein binds to a target sequence within or near a Klotho gene.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: January 9, 2024
    Assignee: Klogenix LLC
    Inventor: Ci-Di Chen
  • Patent number: 11851465
    Abstract: Disclosed is a method for regulating the extracellular secretion ability of a homeoprotein and a homeoprotein variant having regulated extracellular secretion ability using the same, and more particularly, a method for increasing or decreasing the extracellular secretion ability through the increase or decrease in hydrophobicity of an amino acid sequence among homeodomain external amino acid sequences, or a homeoprotein whose extracellular secretion ability is increased or decreased through the increase or decrease in hydrophobicity of the homeodomain external amino acid sequence.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: December 26, 2023
    Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Jin Woo Kim, Eun Jung Lee
  • Patent number: 11845808
    Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: December 19, 2023
    Assignees: Janssen Biotech, Inc., Protagonist Therapeutics, Inc.
    Inventors: Chengzao Sun, Brian Troy Frederick, Sandeep Somani, Gregory Thomas Bourne, Raymond Patch, Ashok Bhandari